News

CCP-07, which is being developed by Tris Pharma, is a cough-cold formulation being developed for the US prescription cough-cold market. The FDA issued complete response letter (CRL) for CCP-07, which

The trial, dubbed EXPEDITION-1, featured patients having chronic hepatitis C virus (HCV) infected patients with genotype 1, 2, 4, 5 or 6 and compensated cirrhosis (Child-Pugh A), and subjected to

H3 and Foundation Medicine will continue to build upon the progress the two companies have made during the collaboration. The companies will collaborate to interrogate the FoundationCORE dataset,

Immune and Pint target closing a final agreement within 30 days. Pursuant to the anticipated final agreement, Pint will be responsible for registration of Ceplene in Latin American

Upsher-Smith’s portfolio includes around 30 pharmaceutical products, specifically intended for oral solid preparations. The acquired business will enables Sawai to develop a US business, in addition to combining R&D

Novartis has also made an undisclosed equity investment in Canada-based Parvus. Under the terms, Novartis will develop and market products made from the Navacim technology besides taking responsibility of its

Patients treated with burosumab demonstrated a statistically significant improvement in serum phosphorus levels, with 94% of patients achieving normal levels compared to 8% on placebo (p<0.0001).  Patients treated

The merger will result in a combined company with a novel protein-based discovery platform focused on inflammation and immuno-oncology. Alpine is focused on developing novel protein-based therapies using

The company presented topline results from the study of Veltassa for oral suspension on hyperkalemia when taken with or without food in patients with hyperkalemia. Veltassa is a potassium